GlassScriptPhysician profile
Sheree Waterous
NPI 1285701060
$3,373.42
in general payments reported to CMS, 2019-2025
25 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $258 · 2022: $351 · 2023: $709 · 2024: $853 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,764.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $760.70 | 2021-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $648.30 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $333.52 | 2022-2025 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $225.78 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $172.99 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $168.61 | 2021-2025 | |
| Madrigal Pharmaceuticals | $141.32 | 2025 | Rezdiffra |
| Pfizer INC. | $134.13 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $124.94 | 2024 | Voquezna |
| Astellas Pharma US INC | $121.82 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.21 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $64.27 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $55.06 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $53.85 | 2022-2025 | |
| Abbott Laboratories | $48.96 | 2023-2024 | Freestyle Libre 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $36.98 | 2025 | |
| Janssen Pharmaceuticals, INC | $25.57 | 2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $24.90 | 2023 | Quviviq |
| Eisai INC. | $24.58 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.89 | 2022 | |
| Paratek Pharmaceuticals, INC. | $21.30 | 2024 | Nuzyra |
| Gilead Sciences, INC. | $18.62 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $18.38 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.76 | 2025 | Recorlev |
| Amarin Pharma, INC. | $16.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheree Waterous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.